2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-178368
    Antibacterial agent 293
    Antibacterial agent 293 (Compound 5) is an antibacterial agent, exhibiting potent anti-Gram-negative bacterial activity. Antibacterial agent 293 shows activity against Escherichia coli, Acinetobacter baumannii and Klebsiella pneumonia. Antibacterial agent 293 can be used for the research of diseases related to Gram-negative bacterial infections.
    Antibacterial agent 293
  • HY-178384
    Antibacterial agent 294
    Antibacterial agent 294 is an antibacterial agent. Antibacterial agent 294 shows antibacterial effect against carbapenem-resistant Acinetobacter baumannii (CRAB) with a MIC of 0.5 μg/mL. Antibacterial agent 294 can be used for the research of infection.
    Antibacterial agent 294
  • HY-178435
    SARS-CoV-2 Mpro-IN-48 98%
    SARS-CoV-2 Mpro-IN-48 is a potent SARS-CoV-2 main protease inhibitor with an IC50 of 21.1 nM. SARS-CoV-2 Mpro-IN-48 exhibits potent antiviral activity against the SARS-CoV-2 JN.1 variant. SARS-CoV-2 Mpro-IN-48 can be used for the research of infection, such as COVID-19.
    SARS-CoV-2 Mpro-IN-48
  • HY-178436
    Antituberculosis agent-16 98%
    Antituberculosis agent-16 is an orally active antituberculosis agent. Antituberculosis agent-16 exhibits stable antituberculosis activity with a MIC of 0.48 μg/mL against Mycobacterium tuberculosis H37Rv sensitive strain and 0.49 μg/mL against multidrug-resistant strain 14862. Antituberculosis agent-16 shows high Caco-2 permeability. Antituberculosis agent-16 can be used for the research of infection.
    Antituberculosis agent-16
  • HY-178439
    SARS-CoV-2 3CLpro-IN-33 2920182-91-6
    SARS-CoV-2 3CLpro-IN-33 (Compound 16) is an orally active SARS-CoV-2 3CL protease inhibitor, with an IC50 value of 1.5 nM. SARS-CoV-2 3CLpro-IN-33 shows excellent anti-SARS-CoV-2 viral activity in the HEK293T-AT cell model with an EC50 of 0.017 μM. SARS-CoV-2 3CLpro-IN-33 can be used for the study of COVID-19 infetction.
    SARS-CoV-2 3CLpro-IN-33
  • HY-178445
    PI3Kδ-IN-27 3097471-25-2 98%
    PI3Kδ-IN-27 is an PI3Kδ inhibitor with an IC50 of 355.3 nM. PI3Kδ-IN-27 exhibits anti-SARS-CoV-2 activity. PI3Kδ-IN-27 can be used for the research of infection, such as COVID-19.
    PI3Kδ-IN-27
  • HY-178449
    Orthopoxviruses-IN-1 3089950-34-2
    Orthopoxviruses-IN-1 (Compound 4) is a potent p37 protein inhibitor (IC50= 0.017 µM against Vaccinia virus (VACV)). Orthopoxviruses-IN-1 is promising for research of orthopoxvirus-related diseases, including variola virus (smallpox) and monkeypox.
    Orthopoxviruses-IN-1
  • HY-178455
    Influenza virus-IN-10 3031321-95-3 98%
    Influenza virus-IN-10 is a dual-target antiviral agents for influenza that targets both PAC (KD = 8.9 μM) and NP (KD = 52.5 μM) simultaneously. Influenza virus-IN-10 exhibits an EC50 values of 1.64 μM) against influenza A virus (H1N1, A/WSN/33) and broad-spectrum activity against other influenza strains, including influenza B virus and multiple subtypes of influenza A.
    Influenza virus-IN-10
  • HY-178456
    Antileishmanial agent-36 3086122-36-0
    Antileishmanial agent-36 (compound 4f) is an indole-dihydropyrimidinone derivative with anti-leishmanial activity. Antileishmanial agent-36 induces reactive oxygen species (ROS)-mediated mitochondrial dysfunction and apoptosis. Antileishmanial agent-36 exhibits potent activity against L. donovani (IC50 =4.54 μM) with low cytotoxicity against J774.1 macrophage. Antileishmanial agent-36 clears the parasite burden in a visceral leishmaniasis (VL) model. Antileishmanial agent-36 can be used for VL research.
    Antileishmanial agent-36
  • HY-178457
    SDH-IN-34
    SDH-IN-34 is a Succinate Dehydrogenase inhibitor with antifungal activity. SDH-IN-34 can be used for the research of infection.
    SDH-IN-34
  • HY-178469
    SDH-IN-35
    SDH-IN-35 (Compound A17) is a potent succinate dehydrogenase (SDH) inhibitor with antifungal activity (EC50=11.9 μM). SDH-IN-35 is promising for research of agricultural fungicide.
    SDH-IN-35
  • HY-178476
    Anti-MRSA agent 36 3096122-10-7
    Anti-MRSA agent 36 (Compound III13) is an antibacterial agent with strong anti MRSA activity (MIC = 1 μg/mL). Anti-MRSA agent 36 targets phosphatidylglycerol (PG) on bacterial membranes, disrupting membrane integrity, leading to DNA leakage and increased ROS. Anti-MRSA agent 36 has advantages such as low cytotoxicity, low hemolysis, difficulty in inducing drug resistance, and good plasma stability. Anti-MRSA agent 36 can be used for the study of skin abscess and systemic infection models.
    Anti-MRSA agent 36
  • HY-178480
    SARS-CoV-2 Mpro-IN-49
    SARS-CoV-2 Mpro-IN-49 (Compound 22e) is a potent SARS-CoV-2 main protease (Mpro) inhibitor (IC50=0.087 μM). SARS-CoV-2 Mpro-IN-49 is promising for research of SARS-CoV-2 and coronavirus.
    SARS-CoV-2 Mpro-IN-49
  • HY-178493
    Anti-MRSA agent 37 3064702-33-3
    Anti-MRSA agent 37 (Compound 5B) is an antibacterial agent against methicillin-resistant Staphylococcus aureus (MRSA) (MIC=0.25-0.5 μg/mL). Anti-MRSA agent 37 inhibits biofilm formation, disrupts cell wall integrit, attacks cell membrane and induces oxidative stress. Anti-MRSA agent 37 is promising for research of MRSA-related diseases such as skin infections.
    Anti-MRSA agent 37
  • HY-178504
    Lug-15
    Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria.
    Lug-15
  • HY-178513
    Anti-MRSA agent 38
    Anti-MRSA agent 38 is a broad-spectrum antibacterial agent (MIC = 0.0625-2 µg/mL). Anti-MRSA agent 38 can inhibit ribosomal protein synthesis. Anti-MRSA agent 38 exerts multiple bactericidal effects by disrupting bacterial membrane structure and inducing ROS accumulation. Anti-MRSA agent 38 can selectively kill tumor cells, such as HGC-27 (IC50 = 0.86 µM), MRC-5 (IC50 = 5.52 µM), and RPC (IC50 = 6.09 µM) cells. Anti-MRSA agent 38 can be used to study infectious diseases such as bacterial infection.
    Anti-MRSA agent 38
  • HY-178695
    E3 Ligase Ligand-linker Conjugate 216
    E3 Ligase Ligand-linker Conjugate 216 is a conjugate of an E3 ligase CRBN ligand and a linker. E3 Ligase Ligand-linker Conjugate 216 can be used to synthesize PROTAC SARS-CoV-2 RdRp Degrader-1 (HY-179283). PROTAC SARS-CoV-2 RdRp Degrader-1 is a SARS-CoV-2 RdRp PROTAC degrader.
    E3 Ligase Ligand-linker Conjugate 216
  • HY-178696
    UAWJ9-36-3 2663864-31-9
    UAWJ9-36-3 is a Mpro and cathepsin L (IC50: 1.81 μM) inhibitor. UAWJ9-36-3 shows potent binding and enzymatic inhibition against the Mpros from SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1. UAWJ9-36-3 demonstrates broad-spectrum antiviral activity against not only SARS-CoV-2, but also the common human coronaviruses HCoV-OC43, HCoV-NL63, and HCoV-229E.
    UAWJ9-36-3
  • HY-178717
    WML-01 3057478-36-8
    WML-01 is a fungicide with EC50s of 0.079, 0.72 and 2.02 μg/mL against F. graminearum, F. fujikuroi and S. sclerotiorum. WML-01 disrupts the cell membrane of F. graminearum and induces deposition of lipid droplets. WML-01 inhibits Deoxynivalenol (DON) (HY-N6684) biosynthesis with no cross-resistance and strongly suppresses ribosomal subunit assembly, impairing protein synthesis. WML-01 effectively controls the fusarium head blight (FHB) epidemic.
    WML-01
  • HY-178739
    Melibionic acid 21675-38-7
    Melibionic acid is a galactose derivative and a ganglioside GD1b inhibitor. Melibionic acid inhibits heat-labile enterotoxin with an IC50 of 7 mM.
    Melibionic acid
Cat. No. Product Name / Synonyms Application Reactivity